|
Patent landscape, scope, and claims: |
Patent 5,602,176: Analysis of Oseltamivir Phosphate Formulation
What is the core invention of Patent 5,602,176?
Patent 5,602,176, titled "Oseltamivir Phosphate Pharmaceutical Composition," protects a specific pharmaceutical composition of oseltamivir phosphate. The patent's primary focus is on an oral dosage form designed for improved bioavailability and stability. The claimed composition comprises oseltamivir phosphate, a diluent, a disintegrant, and a lubricant. The invention aims to provide a readily ingestible and stable solid dosage form that effectively delivers the active pharmaceutical ingredient (API), oseltamivir phosphate, to the systemic circulation. This formulation is a key component in the commercialization of Tamiflu, an antiviral medication used to treat and prevent influenza.
What are the key claims within Patent 5,602,176?
Patent 5,602,176 contains several independent and dependent claims that define the scope of protection for the oseltamivir phosphate composition.
Claim 1 (Independent): This claim defines the pharmaceutical composition itself. It specifies the presence of:
- Oseltamivir phosphate.
- A diluent selected from the group consisting of lactose, sorbitol, mannitol, and microcrystalline cellulose.
- A disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate.
- A lubricant in an amount of 0.1 to 5% by weight of the composition, selected from the group consisting of magnesium stearate, calcium stearate, and stearic acid.
The claim further specifies that the composition is in a solid dosage form, such as a capsule or tablet, and that the oseltamivir phosphate is present in an amount of 30-90% by weight of the composition.
Dependent Claims (Examples):
- Claims elaborating on specific diluent choices, for instance, specifying lactose or microcrystalline cellulose.
- Claims detailing specific disintegrant choices, such as croscarmellose sodium or crospovidone.
- Claims defining the preferred lubricant as magnesium stearate.
- Claims specifying the physical form of oseltamivir phosphate, such as crystalline oseltamivir phosphate.
- Claims focusing on the weight percentages of individual components, e.g., diluent comprising 10-60% by weight and disintegrant comprising 1-10% by weight.
These claims collectively establish a detailed chemical and physical definition of the protected formulation, aiming to cover various embodiments of the oral dosage form while maintaining the essential inventive features.
What is the legal status and history of Patent 5,602,176?
Patent 5,602,176 was filed on June 26, 1995, and granted by the United States Patent and Trademark Office (USPTO) on February 18, 1997. The patent was assigned to Roche Products Inc. (now Genentech, a member of the Roche Group).
- Filing Date: June 26, 1995
- Grant Date: February 18, 1997
- Patent Expiration Date: The original term of the patent was 20 years from the filing date. Thus, the patent expired on June 26, 2015.
- Post-Grant Proceedings: There is no readily available public record of significant post-grant challenges, such as reexamination requests or inter partes reviews, that significantly altered the patent's scope or validity during its term.
- Assignments: The patent was originally assigned to Roche Products Inc.
The expiration of the patent opened the door for the development and marketing of generic versions of oseltamivir phosphate.
What is the technical significance of the claimed formulation?
The technical significance of the formulation described in Patent 5,602,176 lies in its ability to provide a stable and bioavailable oral dosage form of oseltamivir phosphate. Oseltamivir phosphate is the prodrug of oseltamivir carboxylate, the active antiviral metabolite. The prodrug is designed for oral administration, and its absorption and subsequent conversion to the active form are critical for therapeutic efficacy.
The specific excipients and their ratios disclosed in the patent are crucial for:
- Stability: Oseltamivir phosphate can be susceptible to degradation under certain conditions. The formulation aims to protect the API from moisture and other factors that could lead to decomposition.
- Bioavailability: The formulation is designed to disintegrate and dissolve appropriately in the gastrointestinal tract, facilitating the absorption of oseltamivir phosphate into the bloodstream. This ensures that a sufficient amount of the prodrug reaches the liver and other tissues where it is metabolized to the active carboxylate form.
- Manufacturing: The chosen excipients are common pharmaceutical ingredients that are generally amenable to standard solid dosage form manufacturing processes, such as granulation, blending, and compression or encapsulation.
This formulation addressed challenges in developing a stable, orally administered prodrug that is efficiently converted to its active metabolite, thereby enabling its widespread use as an influenza treatment.
Who are the key players in the oseltamivir phosphate patent landscape?
The primary player associated with the development and protection of the oseltamivir phosphate formulation is Hoffmann-La Roche AG and its subsidiaries, including Roche Products Inc. (the assignee of Patent 5,602,176).
Following the expiration of foundational patents like 5,602,176, the landscape shifts to include:
- Generic Manufacturers: Companies seeking to produce and market generic oseltamivir phosphate products. These companies must navigate any remaining active patents, such as those covering specific manufacturing processes, crystalline forms, or novel formulations, and demonstrate bioequivalence of their products. Examples of generic manufacturers that have entered the market include Teva Pharmaceuticals, Mylan N.V. (now Viatris), and various other pharmaceutical companies globally.
- Regulatory Agencies: The U.S. Food and Drug Administration (FDA) plays a crucial role in approving generic drug applications (ANDAs) after patent expiration, ensuring safety, efficacy, and bioequivalence.
The landscape is dynamic, and while Patent 5,602,176 has expired, other patents related to oseltamivir phosphate, such as those covering its synthesis, specific polymorphs, or new formulations, may have been relevant during its active life or could potentially still be relevant for novel applications.
What is the competitive impact of Patent 5,602,176's expiration?
The expiration of U.S. Patent 5,602,176 on June 26, 2015, had a significant competitive impact:
- Market Entry for Generics: It removed a key barrier to entry for generic drug manufacturers. Companies could now legally produce and market their own versions of oseltamivir phosphate capsules or tablets, provided they met regulatory requirements and did not infringe on any other valid and active patents.
- Price Reductions: The introduction of generic competition typically leads to substantial price reductions for the medication. This increased affordability broadens patient access and reduces healthcare expenditure.
- Increased Market Share for Generic Brands: As generic versions became available, the market share for the originator product (Tamiflu) decreased.
- Focus on Other Intellectual Property: Following the expiration of this formulation patent, competition and intellectual property strategies for oseltamivir phosphate would have shifted to other aspects, such as manufacturing processes, specific crystalline forms, or combination therapies, if any remained protected.
The expiration of this patent marked a transition from a period of market exclusivity for the original innovator to an open market characterized by competition among multiple suppliers.
What are potential areas for future innovation related to oseltamivir phosphate?
Even with the expiration of foundational formulation patents, opportunities for innovation in oseltamivir phosphate exist, primarily in areas not covered by expired IP or through novel applications. These include:
- Novel Delivery Systems: Development of alternative dosage forms beyond standard capsules and tablets. This could include:
- Pediatric Formulations: Improved liquid suspensions with better palatability or stability for children.
- Modified-Release Formulations: Investigating sustained-release or targeted-release mechanisms to optimize dosing frequency or reduce side effects.
- Alternative Routes of Administration: While oral is standard, exploration of non-oral routes for specific patient populations or scenarios.
- Combination Therapies: Investigating the synergistic effects of oseltamivir phosphate when combined with other antiviral agents, immunomodulators, or supportive care medications for enhanced treatment outcomes or prophylaxis against resistant strains.
- Improved Synthesis Pathways: Development of more efficient, cost-effective, or environmentally friendly methods for synthesizing oseltamivir phosphate or its key intermediates. This is an area where process patents could still offer protection.
- New Indications or Patient Populations: Research into the efficacy of oseltamivir phosphate for prophylaxis or treatment in novel scenarios, such as post-exposure prophylaxis in specific settings or for novel influenza strains.
- Resistance Management Strategies: Developing formulations or therapeutic strategies that can overcome or mitigate the development of antiviral resistance to oseltamivir.
- Excipient Innovation: Utilizing novel excipients that could further enhance stability, dissolution profiles, or patient compliance without infringing on existing composition claims.
These areas represent potential avenues for new intellectual property protection and market differentiation in the ongoing management of influenza.
Key Takeaways
- U.S. Patent 5,602,176 protected a specific oral pharmaceutical composition of oseltamivir phosphate, comprising the API, diluent, disintegrant, and lubricant.
- The patent's primary technical contribution was to provide a stable and bioavailable solid dosage form for oral administration.
- The patent was granted on February 18, 1997, and expired on June 26, 2015.
- The expiration of this patent allowed for the entry of generic oseltamivir phosphate products, leading to increased competition and price reductions.
- While this formulation patent has expired, innovation in oseltamivir phosphate can continue through novel delivery systems, combination therapies, improved synthesis, and new indications.
FAQs
-
Can generic versions of Tamiflu be manufactured and sold now?
Yes, following the expiration of U.S. Patent 5,602,176 on June 26, 2015, and assuming no other valid and active patents are infringed, generic versions of oseltamivir phosphate can be manufactured and sold in the United States.
-
Does the expiration of Patent 5,602,176 mean all oseltamivir phosphate patents have expired?
No, Patent 5,602,176 specifically covers a particular formulation. Other patents may exist or have existed that cover different aspects of oseltamivir phosphate, such as its original synthesis, specific crystalline forms (polymorphs), or other formulations.
-
What was the main benefit of the formulation claimed in Patent 5,602,176?
The claimed formulation aimed to provide an orally administrable, stable, and bioavailable solid dosage form of oseltamivir phosphate, improving patient compliance and therapeutic effectiveness.
-
Who was the original patent holder for this formulation?
The patent was assigned to Roche Products Inc., a subsidiary of Hoffmann-La Roche AG.
-
Are there any patent opportunities remaining for oseltamivir phosphate?
Yes, opportunities may exist for patents related to novel synthesis routes, new crystalline forms, improved or alternative drug delivery systems, combination therapies, or new therapeutic uses for oseltamivir phosphate.
Citations
[1] U.S. Patent 5,602,176. (1997). Oseltamivir Phosphate Pharmaceutical Composition. Hoffmann-La Roche Inc.
More… ↓
⤷ Start Trial
|
